Early infant growth is associated with the risk of islet autoimmunity in genetically susceptible children

Beyerlein, Andreas; Thiering, Elisabeth; Pflueger, Maren; Bidlingmaier, Martin; Stock, Joanna; Knopff, Annette; Winkler, Christiane; Heinrich, Joachim; Ziegler, Anette‐Gabriele

doi:10.1111/pedi.12118

Cited by 29 publications

(26 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three prospective studies of children at risk for T1DM based on human leukocyte antigen (HLA) genotype or family history have reported more rapid growth to be associated with islet autoimmunity. In a subset of the German BABYDIAB and BABYDIET cohorts (n=1011), a later age at peak infantile BMI (suggestive of less rapid weight gain) was found to be inversely correlated with islet autoimmunity with a hazard ratio (HR) of 0.60 (95% CI 0.41-0.87) per 2 SD increase in age 12 . In a subsequent analysis of a larger subset of this cohort (n=2236), the authors used a clustering technique to define eight specific growth patterns.…”

Section: Growth Prior To the Onset Of T1dmmentioning

confidence: 99%

Growth in patients with type 1 diabetes

Mitchell

2017

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of review As the incidence of type 1 diabetes (T1DM) continues to rise, complications including impairment of childhood growth remain a major concern. This review provides an overview of alterations in growth patterns prior to and after the onset of T1DM. Recent findings Recent advances in this field include several prospective investigations of height and weight trajectories in children leading up to the development of islet autoimmunity and T1DM as well as evaluations of larger cohorts of T1DM patients to better assess predictors of altered growth. In addition, genetic and metabolic investigations have improved our understanding of the more rare severe growth impairment of Mauriac Syndrome. Summary Despite advances in medical care of children with T1DM, growth remains sub-optimal in this population and likely reflects ongoing metabolic derangement linked with classic microvascular diabetic complications.

show abstract

Section: Growth Prior To the Onset Of T1dmmentioning

confidence: 99%

Growth in patients with type 1 diabetes

Mitchell

2017

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

show abstract

“…Greater height prior to and at diagnosis of type 1 diabetes has been reported frequently . The precise mechanism for this and whether or not this increased height is maintained is unclear.…”

Section: Growth Weight Gain and Pubertal Developmentmentioning

confidence: 99%

Other complications and diabetes-associated conditions in children and adolescents

et al. 2014

View full text Add to dashboard Cite

“…Initially, the samples were analyzed for the presence of HLA DQB1*02, DQB1*03:01, DQB1*03:02, and DQB1*06:02/3 alleles, as described by Kiviniemi et al (26). Depending on the result of the initial analysis, the further analyses involved a low-resolution DQB1 fullhouse typing, DQA1 typing with three allele-specific probes, and subtyping of DR4 (25). Samples positive for the DQA1*05-DQB1*02 combination (i.e.…”

Section: Hla Genotypingmentioning

confidence: 99%

“…HLA genotyping was performed with a PCR-based lanthanide-labeled hybridization method using time-resolved fluorometry for detection as previously described (25). Initially, the samples were analyzed for the presence of HLA DQB1*02, DQB1*03:01, DQB1*03:02, and DQB1*06:02/3 alleles, as described by Kiviniemi et al (26).…”

Section: Hla Genotypingmentioning

confidence: 99%

Circulating IGF1 and IGFBP3 in relation to the development of β-cell autoimmunity in young children

Peet

Hämäläinen

Kool

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: This study aimed at investigating the role of IGF1 and IGF binding protein 3 (IGFBP3) in the development of b-cell autoimmunity. Methods: Five hundred and sixty-three subjects with HLA-conferred susceptibility to type 1 diabetes (T1D) were monitored for signs of seroconversion to positivity for insulin and/or GAD, IA2, and zinc transporter 8 autoantibodies by the age of 3 years. In 40 subjects who developed at least one autoantibody, IGF1 and IGFBP3 plasma concentrations were measured and compared with 80 control subjects who remained negative for autoantibodies, and were matched for age, sex, country of origin, and HLA genotype. The increments of IGF1, IGFBP3, and IGF1/IGFBP3 molar ratio before and after seroconverison were compared with corresponding time intervals in controls. Results: The IGF1 concentrations at the age of 12 months and the IGF1/IGFBP3 ratio at the age of 24 months were lower in the autoantibody-positive children (P!0.05). The increase in circulating IGFBP3 was significantly higher in the autoantibodypositive children before seroconversion than in the corresponding time intervals in controls (0.43 mg/l; 95% CI 0.29-0.56 vs 0.22 mg/l; 95% CI 0.10-0.34 mg/l; P!0.01). Children carrying the high-risk HLA genotype had lower plasma IGF1 and IGFBP3 concentrations at the age of 24 months than those with low-risk genotypes (P!0.05 and ! 0.01 respectively). Conclusions: Circulating IGF1 and IGFBP3 appear to have a role in early development of b-cell autoimmunity. The decreased IGF1 concentrations in children with the high-risk HLA genotype may contribute to the reduced growth previously described in such children.

show abstract

Early infant growth is associated with the risk of islet autoimmunity in genetically susceptible children

Abstract: Variations in early growth rate have subtle effects on the risk of islet autoimmunity with growth hormones unlikely to be in the causal pathway.

Cited by 29 publications

References 41 publications

Growth in patients with type 1 diabetes

Growth in patients with type 1 diabetes

Other complications and diabetes-associated conditions in children and adolescents

Circulating IGF1 and IGFBP3 in relation to the development of β-cell autoimmunity in young children

Contact Info

Product

Resources

About